Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

Such payment by Daiichi Sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that include gatipotuzumab as part of a 2018 licensing ...

BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new ...

Call for Research Proposals The BioMed X Institute and Daiichi Sankyo are inviting proposals from researchers ... We are not an agent for these third parties nor do we endorse or guarantee their ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Besides apartments and cars, smartphone sales are also booming. The number of registered smartphones among Vietnam’s 100 ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...

Cengage Group, a global edtech company, today announced the acquisition of Visible Body, a leader in interactive, 3D models ...

ServiceNow today announced that it will release financial results for the fourth quarter and full-year ended December 31, 2024, following the close of market on Wednesday, January 29, 2025. ServiceNow ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...